Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.

Ben O'Leary,Ros Cutts,Xin Huang,Sarah Hrebien,Yuan Liu,Isaac Garcia-Murillas,Fabrice Andre,Sherene Loi,Sibylle Loibl,Massimo Cristofanilli,Cynthia Huang Bartlett,Nicholas C. Turner

Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.

2019

Ben O'Leary
Ros Cutts
Xin Huang
Sarah Hrebien
Yuan Liu
Isaac Garcia-Murillas
Fabrice Andre
Sherene Loi
Sibylle Loibl
Massimo Cristofanilli
Cynthia Huang Bartlett
Nicholas C. Turner

1010Background: Markers of early progression on endocrine therapy in combination with CDK4/6 inhibitors remain limited despite the key role of these combinations in treating of ER+ advanced breast ...

Keywords:

Palbociclib
Endocrine system
Fulvestrant
Breast cancer
Pathology
Oncology
Medicine
Internal medicine
endocrine therapy
Cancer
advanced breast

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations